Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19412682 | 0.71 | BCHE (0.35) | BCHE | |
| SCHEMBL24158036 | 0.71 | BCHE (0.44) | BCHEOPRM1OPRL1CYP2C19 | |
| SCHEMBL19101726 | 0.71 | CTSV (0.39) | BCHEPDPK1MTORIDO1CYP2C19 | |
| SCHEMBL18699958 | 0.71 | PDE4D (0.38) | BCHEGRM2GRM3PDPK1MTOR | |
| SCHEMBL23047613 | 0.70 | BCHE (0.38) | BCHEOPRM1OPRL1PDE4DALDH1A1 | |
| SCHEMBL19650285 | 0.70 | MAPT (0.38) | BCHEIDO1ALDH1A1CYP2C19 | |
| SCHEMBL19962794 | 0.70 | BCHE (0.38) | BCHEGRM2GRM3PDPK1MTOR | |
| SCHEMBL19292430 | 0.70 | CTSV (0.38) | BCHEGRM2GRM3PDPK1MTOR | |
| SCHEMBL23278062 | 0.69 | IDO1 (0.37) | BCHEGRM2GRM3PDPK1MTOR | |
| SCHEMBL7901242 | 0.68 | PDPK1 (0.54) | BCHEPDPK1MTORIDO1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | BCHE 3851/4885GRM2 3501/4885GRM3 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.